Background:
Delirium tremens (DTs) is a severe manifestation of alcohol withdrawal.
Pearson first described it in 1813 as an acute psychosis following abstinence
from alcohol. Although it only occurs in a relatively small number of patients
who undergo alcohol withdrawal, it can be fatal. DTs is a medical emergency that
requires prompt recognition and treatment.
Pathophysiology: Chronic intake of alcohol affects several
of the neurotransmitter systems in the brain. These effects include increased
release of endogenous opiates; activation of the gamma-aminobutyric acid-A
(GABA-A) receptor and a decrease in GABA-A receptor function, with resultant
influx of chloride ions; inhibition of the N-methyl-D-aspartate (NMDA)
type of glutamate receptor, which mediates the postsynaptic excitatory effects
of glutamate, with up-regulation of this receptor; and interactions with
serotonin and dopamine receptors. During withdrawal from alcohol, the loss of
GABA-A receptor stimulation causes a reduction in chloride flux and is
associated with tremors, diaphoresis, tachycardia, anxiety, and seizures. In
addition, the lack of inhibition of the NMDA receptors may lead to seizures and
delirium. Excessive nervous system excitability during periods of abstinence
from alcohol is related to the effect of alcohol on the number and function of
brain receptors.
Frequency:
In the US: DTs occurs in 5% of patients with alcohol
withdrawal.
Mortality/Morbidity: Despite appropriate treatment, the
current mortality for patients with DTs ranges from 5-15%. Mortality was as high
as 35% prior to the era of intensive care and advanced pharmacotherapy. The most
common conditions leading to death in these patients are respiratory failure and
cardiac arrhythmias.
CLINICAL
History:
Alcohol withdrawal syndrome is the clinical syndrome that occurs when
people who are physically dependent upon alcohol stop drinking or reduce their
alcohol consumption. Alcohol withdrawal syndrome is divided into 4 categories.
Minor withdrawal (withdrawal tremulousness) occurs within 6-24 hours
following the last drink and is characterized by tremor, anxiety, nausea,
vomiting, and insomnia.
Major withdrawal (hallucinations) occurs 10-72 hours after the last drink.
The signs and symptoms include visual and auditory hallucinations, whole body
tremor, vomiting, diaphoresis, and hypertension.
Withdrawal seizures (rum fits) occur within 6-48 hours of alcohol
cessation and are characterized by major motor seizures that occur during
withdrawal in patients who normally have no seizures and have normal EEGs. In
60% of patients, the seizures are multiple, but only 3% of patients go on to
develop status epilepticus. About 30-40% of patients with alcohol withdrawal
seizures progress to DTs.
DTs is the most severe manifestation of alcohol withdrawal. It occurs 3-10
days following the last drink. Clinical manifestations include agitation,
global confusion, disorientation, hallucinations, fever, and autonomic
hyperactivity (tachycardia and hypertension).
The most objective tool to assess the severity of alcohol withdrawal is
the Clinical Institute Withdrawal Assessment for Alcohol, Revised
(CIWA-Ar).
This survey consists of 10 items and can be administered rapidly at the
bedside.
This scale has been demonstrated to have high reliability,
reproducibility, and validity based on comparisons with ratings by
experienced clinicians and has been shown to be usable in detoxication
units, psychiatry units, and hospital medical/surgical wards.
A score of greater than 15 is considered to be significant for alcohol
withdrawal, and these patients need to be monitored carefully for the
development of DTs.
Physical:
No specific findings on physical examination are diagnostic for DTs.
However, DTs often presents with a coexisting illness, so a careful physical
examination should be performed in order to uncover any potentially serious
illness that may be present.
Physical examination findings in a patient with DTs may include fever,
hypertension, tachycardia, diaphoresis, tremor, agitation, positional
nystagmus, global confusion, and disorientation.
Causes: Risk factors for developing DTs include coexisting
acute illness, long duration of alcohol intake, large volume of alcohol intake,
severe withdrawal symptoms at presentation, prior DTs, prior seizures, prior
detoxification, and intense craving for alcohol.
AIDS and HIV Cerebral embolism Cerebral hemorrhage Cerebral
tumors Encephalitis Hypoxia Raised intracranial pressure Substance
intoxication and withdrawal Toxic ingestions or exposures (eg, methanol,
salicylates, ethylene glycol, carbon monoxide, anticholinergics) Vitamin B-12
deficiency Thyrotoxicosis
WORKUP
Lab Studies:
Serum ethanol level
Serum chemistry to include:
Sodium
Potassium
Chloride
Bicarbonate
Blood urea nitrogen (BUN)
Creatinine
Magnesium
Phosphorous
Serum glucose
Complete blood count with differential
Drug screen, if suspicion of drug use is present
Measure serum anticonvulsant levels if the patient is known or suspected
to be taking anticonvulsant medication.
Imaging Studies:
Chest radiograph
About 50% of patients with DTs who present with fever will have an
infection, pneumonia being most common.
A chest radiograph should be obtained on all patients suspected of
having DTs.
Obtain cervical spine series if any question or suspicion of trauma or
head injury exists.
CT scanning of the head is performed selectively. Indications for a head
CT scan include the following:
New-onset seizure
Seizures occurring over longer than a 6-hour period
More than 6 seizures
Focal seizures
Evidence of head trauma
Focal neurologic deficits
A prolonged postictal state
Deteriorating level of consciousness
Procedures:
Lumbar puncture
Patients with alcohol withdrawal syndrome who have had a seizure and
continue to be obtunded should have a lumbar puncture if no signs of
increased intracranial pressure are present.
Some patients may not have the classic signs of meningitis, such as
nuchal rigidity, and the cerebrospinal fluid (CSF) of these patients should
be examined to rule out meningitis. CSF pleocytosis often is present after
withdrawal seizures, even in the absence of infection or intracranial
bleeding. However, CSF pleocytosis after seizures should not be attributed
solely to the seizures without a search for a treatable infectious cause.
Even in the absence of seizures, perform lumbar puncture if any suspicion of
meningitis exists (fever, lethargy, confusion, or headache). The absence of
nuchal rigidity does not reliably rule out meningitis in these
patients.
TREATMENT
Medical Care:
Supportive therapy is an important component of the treatment of
alcohol withdrawal syndrome and DTs. This includes providing a calm quiet
environment, reassurance, ongoing reassessment, attention to fluid and
electrolyte deficits, and treatment of any coexisting addictions. Commonly,
these patients have coexisting medical, surgical, and psychiatric conditions
that need careful diagnosis and treatment.
Thiamine is useful in preventing Wernicke encephalopathy (confusion,
ataxia, ophthalmoplegia) and Korsakoff syndrome. Thiamine has no effect on the
symptoms or signs of alcohol withdrawal or on the incidence of seizures or
DTs. Routine use of thiamine is recommended because the development of
Wernicke encephalopathy or Korsakoff syndrome is disastrous in these patients
and can remain unrecognized.
Multivitamins and folate frequently are administered to these patients,
but no evidence exists that vitamins, other than thiamine, have any benefit in
the acute setting.
Administer IV fluids for rehydration, as necessary. Most patients with
severe alcohol withdrawal are significantly dehydrated, and their fluid
requirements range from 4-10 liters in the first 24 hours. Because
hypoglycemia is common in these patients due to depleted glycogen stores, a 5%
dextrose solution (in 0.90% or 0.45% saline) should be used to prevent
hypoglycemia.
Monitor and replace electrolytes as necessary because people with
alcoholism often have low calcium, magnesium, phosphorous, and
potassium.
People with alcoholism frequently have large total body deficits of
magnesium. Symptoms and signs of magnesium deficiency include hyperactive
reflexes, weakness, tremor, refractory hypokalemia, reversible
hypoparathyroidism with hypocalcemia, and cardiac dysrhythmias. Serum
magnesium levels often are normal in spite of a total body magnesium
deficit, and magnesium levels that are initially low may return to normal
even though a total body deficiency persists. Because administration of
magnesium is safe in the absence of renal insufficiency, consider routine
administration of magnesium in patients with alcohol withdrawal. In severe
deficiency, the deficit is about 1-2 mEq/kg of body weight.
When magnesium is administered intravenously to patients without renal
insufficiency, about 50% of a dose is excreted into the urine and not
retained by the body. About half of the deficit should be replaced in the
first 24 hours. For a 70-kg person with normal renal function, 4-6 g of
magnesium sulfate (32-48 mEq of magnesium) is administered by continuous
intravenous infusion on the first day, followed by half that amount daily
for 4 days. Alternatively, the same daily dose of magnesium can be
administered intramuscularly at 6- to 8-hour intervals. Oral administration
of magnesium-containing antacids can be effective but is limited by the
development of diarrhea.
Aspiration precautions often are necessary. This may include placing the
patient in the left lateral decubitus position or intubating the patient,
depending on the patient's level of consciousness. Also, the patient should
not be administered any oral medications or fluids.
MEDICATION
Though thiamine has
no effect on the symptoms or signs of alcohol withdrawal or on the incidence of
seizures or DTs, thiamine (100 mg PO/IV/IM qd for 3 d) is useful in preventing
Wernicke encephalopathy (confusion, ataxia, ophthalmoplegia) and Korsakoff
syndrome. Multivitamins (PO/IV qd) and folate (1 mg PO/IV qd) frequently are
administered to these patients, but no evidence exists that vitamins, other than
thiamine, have any benefit in the acute setting.
Many varying pharmacotherapeutic management recommendations exist for alcohol
withdrawal and DTs. Even many authoritative textbooks and journal articles have
made recommendations for use of pharmacotherapeutic agents that have never been
tested in clinical trials for this condition.
Benzodiazepines are considered the drugs of choice for the management of all
stages of the alcohol withdrawal syndrome, including DTs. Not only do they have
a high margin of safety, but also prospective randomized clinical trials have
demonstrated that benzodiazepines are very effective in treating the symptoms
and signs of alcohol withdrawal and in decreasing the incidence of seizures and
DTs. The longer-acting benzodiazepines, such as chlordiazepoxide and diazepam,
appear to be more effective at preventing the serious complications of seizures
and DTs than shorter-acting benzodiazepines such as alprazolam and oxazepam.
Most experts recommend that intermittent IV bolus dosing of diazepam or
lorazepam is the treatment of choice for drug therapy of DTs.
Phenobarbital, a long-acting barbiturate, has been used successfully in the
treatment of alcohol withdrawal and DTs. It has well-documented anticonvulsant
activity, is inexpensive, and can be administered by the oral, intramuscular, or
intravenous route. However, compared to benzodiazepines, even at high doses,
phenobarbital has a greater risk of respiratory depression and hypotension and
has a lower overall safety profile. Therefore, only use phenobarbital as an
alternative agent when benzodiazepines cannot be used or have not been
effective.
An appropriate use for phenobarbital might be the situation in which
agitation has not been controlled well with high doses of benzodiazepines. Then,
one could administer a small dose of phenobarbital (60-120 mg) and repeat every
30 minutes until sedation occurs. For patients with refractory DTs, propofol
recently has been described in case studies as effective in managing patients
who are intubated. No clinical trial has demonstrated any superiority over
benzodiazepines.
Clonidine and beta-blockers have been used to treat the hyperadrenergic state
of alcohol withdrawal. Although these agents may correct some of the autonomic
manifestations of withdrawal, they have not been demonstrated to have any effect
on seizures or DTs, and they should only be used in conjunction with
benzodiazepines in the treatment of patients with alcohol withdrawal. The
recommended dose for clonidine is 0.2 mg orally bid, but this dose should be
individualized. The recommended dose for atenolol is 50 mg orally once per day
for heart rate of 50-79 beats per minute, 100 mg once daily for heart rate
greater than 80 beats per minute, and no drug is administered if heart rate is
less than 50 beats per minute. The usual contraindications for clonidine and
beta-blockers apply.
Carbamazepine has been shown in some clinical trials to be effective in
treating patients with minor symptoms of alcohol withdrawal and has been used
extensively in Europe as monotherapy. No evidence exists to indicate that
carbamazepine is effective in prevention or treatment of DTs.
Drugs such as esmolol and midazolam, which have a short half-life and rapid
onset of action, can be administered by continuous intravenous infusion and have
been used in critically ill patients with DTs. Clinical studies have not shown
them to be superior or even equal in overall effectiveness compared to
longer-acting agents.
Drug Category: Benzodiazepines -- By acting on
the GABA receptor, benzodiazepines produce a cross-tolerance to alcohol, thus
reducing the hemodynamic and peripheral symptoms of alcohol withdrawal. The dose
of benzodiazepine used should be based on the patient's symptoms and signs of
alcohol withdrawal, including vital signs and amount of agitation. The
longer-acting agents appear to be superior compared to the short-acting agents
and may result in a smoother withdrawal course with less breakthrough and
rebound symptoms, although a risk of excessive sedation exists in certain
patient groups (elderly patients, patients with liver failure) with the
longer-acting agents.
For the treatment of minor or moderate alcohol withdrawal (patient able to
take oral therapy), symptom-triggered therapy has been shown in prospective
randomized controlled trials to be superior to fixed-dose drug therapy, with
less medication use and a shorter duration of therapy. The dosage of
benzodiazepine needs to be individualized for each patient. Drug regimens and
doses recommended for minor withdrawal are not appropriate for patients with
DTs, who often require very high doses of these agents. For the treatment of
DTs, benzodiazepines should only be administered parenterally.
For patients with severe withdrawal symptoms, including DTs, the
benzodiazepine dose should be front-loaded. That is, large doses should be
administered intravenously at short intervals until the patient is calm but
easily aroused. Then additional doses are administered only as needed. Most
authorities recommend intravenous diazepam as the first choice for front-loading
treatment of severe alcohol withdrawal. Because of its long serum half-life, and
the even longer half-life of its active metabolite (desmethyldiazepam),
additional doses may not be required once the patient is calm.
The use of continuous infusions of short-acting benzodiazepines (lorazepam,
midazolam) has been reported, but these infusions have required very large
amounts of drug and are very expensive. No evidence indicates that continuous
infusion therapy with short-acting agents leads to better outcomes than oral or
intravenous intermittent bolus therapy with long-acting agents.
Drug Name
Chlordiazepoxide (Librium, Libritabs,
Mitran) -- Depresses all levels of CNS, including limbic and reticular
formation, possibly by increasing GABA activity, a major inhibitory
neurotransmitter. Parenteral form usually used initially. Because of
limited experience with IV chlordiazepoxide for severe alcohol withdrawal
and DTs, the use of intravenous diazepam or lorazepam is preferred.
Adult Dose
Minor
withdrawal: Symptom-triggered therapy (preferred): 50-100 mg PO
q1-2h until symptoms are controlled, then prn based on
symptoms Fixed-schedule dosing (not recommended): 50 mg PO q6h for
4 doses, then 25 mg q6h for 8 doses; additional 25- to 50-mg doses prn
based on symptoms
Coadministration with alcohols,
phenothiazines, barbiturates, and MAOIs increases CNS toxicity
Pregnancy
D - Unsafe in pregnancy
Precautions
Caution in patients receiving other CNS
depressants, patients diagnosed with low albumin levels, or hepatic
failure
Drug Name
Diazepam (Valium, Diazemuls, Diastat) --
Depresses all levels of CNS (eg, limbic and reticular formation), possibly
by increasing activity of GABA. Individualize dosage and increase
cautiously to avoid adverse effects.
Adult Dose
Minor
withdrawal: Symptom-triggered therapy (preferred): 10-20 mg PO
q1-2h until symptoms controlled, then repeat prn Fixed-schedule
dosing (not recommended): 10 mg PO q6h for 4 doses, then 5 mg q6h for 8
doses; additional 5- to 10-mg doses prn based on symptoms DTs:
10 mg IV, followed by 5 mg q5min until patient is calm but awake
Increased toxicity of benzodiazepines in
CNS with coadministration of phenothiazines, barbiturates, alcohols, and
MAOIs
Pregnancy
D - Unsafe in pregnancy
Precautions
Caution in elderly patients (>60 y) or
hepatic dysfunction, such as cirrhosis or abnormal liver function
(prothrombin time >14 s or total bilirubin >2mg/dL) because toxicity
may increase; caution in patients with renal failure because accumulation
of active metabolites can occur; diazepam has a long-acting active
metabolite, desmethyldiazepam, which can accumulate after repeated large
doses, especially in elderly patients or those with renal insufficiency,
although toxic serum levels of diazepam and its metabolite have not been
reported in patients with DTs, even after very large doses of
drug Caution in severely depressed patients; be aware that diazepam
can produce psychological and physical dependence; rarely, very large
doses of diazepam administered IV (several hundred mg daily for several
days) have been reported to result in an elevated anion gap metabolic
acidosis due to accumulation of the propylene glycol component of the
carrier solution; diazepam can produce thrombophlebitis when injected into
small peripheral veins
Drug Name
Lorazepam (Ativan) -- Sedative hypnotic
with short onset of effects and relatively long half-life. By increasing
action of GABA, which is major inhibitory neurotransmitter in brain, may
depress all levels of CNS, including limbic and reticular formation. When
patient must be sedated for longer than 24-h period, this medication is
excellent. Commonly used prophylactically to prevent DTs. Has a medium
half-life. It is especially useful in elderly persons and in those with
hepatic dysfunction because it does not produce active metabolites.
Adult Dose
Minor
withdrawal: Symptom-triggered therapy (preferred): 2-4 mg PO/IV/IM
q1-2h prn to control symptoms Fixed-schedule dosing (not
recommended): 2 mg PO/IV/IM q6h for 4 doses, then 1 mg q6h for 8 doses;
additional 1- to 2-mg doses prn if symptoms not controlled DTs:
1-2 mg IV q5min until patient is calm but awake
Toxicity of benzodiazepines in CNS
increases when used concurrently with alcohol, phenothiazines,
barbiturates, and MAOIs
Pregnancy
D - Unsafe in pregnancy
Precautions
Caution in renal or hepatic impairment,
myasthenia gravis, organic brain syndrome, or Parkinson disease; rarely,
very large doses administered IV (several hundred mg daily for several
days) have been reported to produce elevated anion gap metabolic acidosis
due to the propylene glycol component
Drug
Category: Anesthetic agents -- Propofol, an intravenous
anesthetic agent, is active on both the glutamate and GABA-A receptors, similar
to the alcohol itself, whereas benzodiazepines are active only against the GABA
receptors. It may be effective for patients with DTs refractory to
benzodiazepines. Due to its rapid onset of hypnosis and anticonvulsant
properties, propofol is an alternative treatment for intubated patients with DTs
refractory to high-dose benzodiazepines. Advantages to its use are that it is
easily titratable with predictable effects and has a rapid metabolic clearance.
Drug Name
Propofol (Diprivan) -- Phenolic compound
unrelated to other types of anticonvulsants. Has general anesthetic
properties when administered IV. Propofol IV produces rapid hypnosis,
usually within 40 s. Effects are reversed within 30 min following
discontinuation of infusion.
Adult Dose
Bolus IV injection of 0.5 mg/kg q10s to a
total dose of 2-2.5 mg/kg or by continuous infusion at 25-75 mcg/kg/min
Pediatric Dose
Not established
Contraindications
Documented hypersensitivity; those who
are not mechanically ventilated
Interactions
Reduce propofol dose when administered
concomitantly with benzodiazepines, opiates, phenothiazines, ethanol, and
narcotics; propofol may potentiate neuromuscular blockade of vecuronium;
theophylline may weaken effects of propofol, and dose increase may be
needed
Pregnancy
B - Usually safe but benefits must
outweigh the risks.
Precautions
Do not administer with blood or blood
products using the same IV catheter; patients may develop apnea; may
experience a decrease in systemic vascular resistance leading to
hypotension; prolonged use (>72 h) may result in hyperlipidemia
(hypertriglyceridemia) due to its high lipid load; propofol-induced
hypertriglyceridemia may cause pancreatitis in patients with alcohol
withdrawal syndrome; monitor serum triglyceride levels when propofol is
used for >72 h
FOLLOW-UP
Further Inpatient Care:
Once patients with DTs have been stabilized, further dosing with
benzodiazepines will be needed to manage their alcohol withdrawal. A
symptom-triggered dosing regimen, rather than fixed-schedule dosing, is the
current preferred regimen. Fixed-dose regimens often result in excessive
sedation.
Alcohol withdrawal seizures are generalized and usually are single or
recur only once or twice. These seizures generally resolve spontaneously. If a
patient has a seizure that is not typical of an alcohol withdrawal seizure
(such as a focal seizure), the underlying cause of the seizure should be
investigated.
The use of benzodiazepines has been shown to prevent initial and recurrent
seizures. Phenytoin is not indicated for the prophylaxis or treatment of these
seizures.
Indications for hospital admission of a patient with alcohol withdrawal
syndrome include DTs; severe symptoms such as hallucinations, disorientation,
confusion, autonomic hyperactivity, or extreme agitation; the presence of a
medical or surgical condition requiring treatment; a recent history of head
injury with loss of consciousness; recurrent seizures; partial seizures; or
focal neurologic findings on examination.
Further Outpatient Care:
As an outpatient, the issue of alcohol dependence must be
addressed.
Alcohol cessation programs and support groups, such as Alcoholics
Anonymous, should be recommended.
In addition, pharmacologic aids to alcohol cessation can be considered.
Disulfiram is the most commonly used medication for this purpose, and
naltrexone has been used more recently with some limited
success.
MISCELLANEOUS
Medical/Legal Pitfalls:
Failure to consider the diagnosis of alcohol withdrawal syndrome in
patients with altered mental status or abnormal vital signs is a potential
pitfall.
Failure to treat patients with severe alcohol withdrawal syndrome with
adequate doses of benzodiazepines is a potential pitfall because these
patients may require extremely large doses of parenteral
benzodiazepines.
Making the assumption that all seizures in people with alcoholism are due
to alcohol withdrawal without considering other causes of seizures, such as
infection, hemorrhage, or trauma, is a potential pitfall.
Failure to exclude other etiologies of altered mental status in patients
with suspected alcohol withdrawal is a potential pitfall.
Failure to admit patients to the hospital with signs and symptoms of major
withdrawal or DTs is a potential pitfall.
Use of a sympatholytic drug (ie, clonidine, atenolol) alone or with
inadequate doses of benzodiazepines potentially can cause problems because use
of these drugs provides a false sense of security by correcting some of the
autonomic manifestations of withdrawal in a patient who may be progressing to
DTs. Sympatholytic drugs should not be administered unless adequate doses of
benzodiazepines also are administered.
Use of phenytoin to prevent or treat alcohol withdrawal seizures is not
recommended. Phenytoin is not effective in preventing or treating alcohol
withdrawal seizures. Seizures due to alcohol withdrawal are best prevented and
treated with benzodiazepines.
Use of neuroleptic drugs (phenothiazines, butyrophenones) alone to treat
agitation or hallucinations caused by alcohol withdrawal potentially can cause
problems because these drugs are not effective in preventing or treating DTs
and may increase the risk of seizures. Use of a small dose of a butyrophenone,
such as haloperidol, may be useful as adjunctive therapy to treat agitation
and hallucinations, as long as adequate doses of benzodiazepines have been
administered.
The use of alcohol to prevent or treat alcohol withdrawal and DTs is not
recommended. Alcohol has multiple toxicities, including pancreatitis,
hepatitis, cardiomyopathy, gastritis, and bone marrow suppression. It also has
a short half-life and requires monitoring of blood levels when used
intravenously, and its use may appear to condone alcohol intake in the patient
with alcoholism who is beginning recovery. Alcohol treatment has not been
shown in controlled trials to be effective in preventing seizures or
DTs.
Constructed
by Dr N.A. Nematallah Consultant in perioperative medicine and intensive
therapy, Al Razi Orthopedic Hospital ,
State of Kuwait, email : razianesth@freeservers.com